immunotherapy options for nsclc: nivolumab, pembrolizumab or atezolizumab?
Published 6 years ago • 1.2K plays • Length 0:49Download video MP4
Download video MP3
Similar videos
-
3:30
immunotherapy treatments for non-small cell lung cancer (nsclc)
-
3:08
choosing immunotherapy as front line therapy for non-actionable nsclc
-
2:12
real-world study of atezolizumab vs. pembrolizumab for advanced/metastatic uc
-
3:44
immunotherapy as combination and neoadjuvant therapies in nsclc
-
1:46
immunotherapy for lung cancer and trial of ramucirumab plus pembrolizumab
-
4:02
immunotherapy options for lung cancer variations
-
1:02
pembrolizumab monotherapy for nsclc: keynote-024 update
-
0:48
chemotherapy-free immunotherapy-based treatment approaches for nsclc
-
1:13
a new standard of care for advanced lung cancer: what’s next for pembrolizumab?
-
2:43
clinical factors in the selection of patients for first-line immunotherapy of lung cancer
-
2:44
advances in perioperative immunotherapy in lung cancer
-
3:43
immunotherapy for operable lung cancer
-
4:18
impower110: atezolizumab vs chemo in pd-l1–selected nsclc
-
1:41
adjuvant atezolizumab in nsclc
-
0:56
pembrolizumab and the significance of pd-l1 for lung cancer
-
1:26
progression is progression! the importance of monitoring the efficacy of immunotherapy in nsclc
-
1:56
dr. levy on impact of nivolumab, pembrolizumab approvals in nsclc
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
2:22
moving immunotherapy to earlier lines in nsclc